ABUS (Arbutus Biopharma) Long-Term Capital Lease Obligation : $0.63 Mil (As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Long-Term Capital Lease Obligation?

Arbutus Biopharma's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.63 Mil.

Arbutus Biopharma's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 ($0.98 Mil) to Dec. 2024 ($0.81 Mil) and declined from Dec. 2024 ($0.81 Mil) to Mar. 2025 ($0.63 Mil).

Arbutus Biopharma's annual Long-Term Capital Lease Obligation declined from Dec. 2022 ($1.82 Mil) to Dec. 2023 ($1.34 Mil) and declined from Dec. 2023 ($1.34 Mil) to Dec. 2024 ($0.81 Mil).

Arbutus Biopharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Arbutus Biopharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Long-Term Capital Lease Obligation Chart

Arbutus Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.59

2.23

1.82

1.34

0.81

Arbutus Biopharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.18	1.14	0.98	0.81	0.63

Arbutus Biopharma (NAS:ABUS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Arbutus Biopharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

I9DN:Germany I9DN:Germany

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Executives

Karen Sims	officer: Chief Medical Officer	701 VETERANS CIRCLE, WARMINSTER PA 18974
David C Hastings	officer: Chief Financial Officer	C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
J. Christopher Naftzger	officer: General Counsel and CCO	633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Mcelhaugh	officer: Chief Business Officer	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Keith S Manchester	director	C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Michael J. Sofia	officer: Chief Scientific Officer	C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Tram Tran	director	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers	director	GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng	director	170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier	director, officer: President and CEO	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard	officer: Executive VP & General Counsel	100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8